.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,797,413

« Back to Dashboard

Claims for Patent: 4,797,413

Title: Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
Abstract:Aromatic sulfonamides with a saturated heterocycle fused thereto are carbonic anhydrase inhibitors useful in the treatment of elevated intraocular pressure.
Inventor(s): Baldwin; John J. (Gwynedd Valley, PA), Ponticello; Gerald S. (Lansdale,, PA), Christy; Marcia E. (Collegeville, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:07/067,326
Patent Claims: 1. A compound of structural formula: ##STR30## or a pharmacologically acceptable salt thereof, wherein: X is --S--, --SO--, or --SO.sub.2 --;

Y is --S--, C.sub.1-3 alkyl or benzyl,

m is 1

R.sup.13 is

(a) hydrogen,

(b) phenyl either unsubstituted or substituted with one or more of

(1) hydroxy,

(2) C.sub.1-3 alkoxy,

(3) R.sup.17 R.sup.18 N-C.sub.1-5 alkyl, wherein R.sup.17 and R.sup.18 are independently selected from:

(i) hydrogen or

(ii) C.sub.1-5 alkyl, or taken together with the nitrogen to which they are attached form a heterocycle selected from morpholine, piperidine, pyrrolidine, and piperazine,

(c) -OH,

(d) =O; or

(e) -NR.sup.17 R.sup.18

R.sup.14 is

(a) hydrogen,

(b) --CN,

(c) phenyl-C.sub.1-3 alkyl, wherein the phenyl is either unsubstituted or substituted with one or more of

(1) hydroxy,

(2) C.sub.1-3 alkoxy, or

(3) R.sup.17 R.sup.18 N-C.sub.1-5 alkyl;

R.sup.15 is

(a) hydrogen,

(b) C.sub.1-5 alkyl,

(c) phenyl-C.sub.1-3 alkyl, wherein the phenyl is either unsubstituted or substituted with on or more of:

(1) hydroxy,

(2) C.sub.1-3 alkoxy,

(3) R.sup.17 R.sup.18 N-C.sub.1-3 alkyl,

(d) phenyl either unsubstituted or substituted with one or more of

(1) hydroxy,

(2) C.sub.1-3 alkoxy,

(3) R.sup.17 R.sup.18 N-C.sub.1-3 alkyl, or

(4) chloro or fluoro

(e) aromatic heterocycle of 5 or 6 members selected from furyl, pyridyl, and thienyl either unsubstituted or substituted with R.sup.17 R.sup.18 N-C.sub.1-3 alkyl,

(f) --NR.sup.17 R.sup.18 ; and

(g) C.sub.2-5 alkyl substituted with --NR.sup.17 R.sup.18

R.sup.16 is

(a) hydrogen, or

(b) C.sub.1-3 alkyl,

with the proviso that if R.sup.13 is other than phenyl or substituted phenyl and R.sup.14 is hydrogen, one of R.sup.15 and R.sup.16 is other than hydrogen.

2. The compound of claim 1, wherein X is --SO.sub.2 --, R.sup.13 is H or --NR.sup.17 R.sup.18, R.sup.14 is hydrogen, R.sup.16 is hydrogen or C.sub.1-3 alkyl and R.sup.15 is C.sub.1-5 alkyl, C.sub.2-5 alkyl substituted with R.sup.17 R.sup.18 --N--, or phenyl substituted with hydroxy and/or R.sup.17 R.sup.18 N-C.sub.1-3 alkyl.

3. The compound of claim 2 wherein R.sup.15 is phenyl substituted with --OH and/or R.sup.17 R.sup.18 N-C.sub.1-3 alkyl.

4. The compound of claim 2, of structural formula: ##STR31##

5. The compound of Claim 3, of structural formula: ##STR32##

6. The compound

5,6,-dihydro-4-ethylamino-6-methyl-4H-thieno[2,3-b]thiopyran-2-sulfonamide- 7,7-dioxide and its (-)-trans-enantiomer;

5,6-dihydro-4-(2-methylpropylamino)-6-methyl-4H-thieno[2,3-b]thiopyran-2-su lfonamide-7,7-dioxide and its (-)-trans-enantiomer;

5,6-dihydro-6,6-dimethyl-4-ethylamino-4H-thieno[2,3-b]thiopyran-2-sulfonami de-7,7-dioxide;

5,6-dihydro-5-(3-dimethylaminomethyl-4-hydroxybenzyl)-4H-thieno[2,3-b]thiop yran-2-sulfonamide-7,7-dioxide;

5,6-dihydro-6-(3-dimethylaminomethyl-4-hydroxyphenyl)-4H-thieno[2,3-b]thiop yran-2-sulfonamide-7,7-dioxide; or

5,6-dihydro-6-(ethylaminoethyl)-4H-thieno[2,3-b]thiopyran-2-sulfonamide-7,7 -dioxide.

7. The compound (-)-trans-5,6-dihydro-4-ethylamino-6-methyl-4H-thieno[2,3-b]thiopyran-2-su lfonamide-7,7-dioxide.

8. An ophthalmological formulation for the treatment of ocular hypertension comprising an ophthalmologically acceptable carrier and an effective ocular antihypertensive amount of a compound of claim 1.

9. An ophthalmological formulation for the treatment of ocular hypertension comprising an ophthalmologically acceptable carrier and an effective ocular antihypertensive amount of the compound of claim 6.

10. An ophthalmological formulation for the treatment of ocular hypertension comprising an ophthalmologically accetable carrier and an effective ocular antihypertensive amount of the compound of claim 7.

11. A method of treating ocular hypertension comprising topical ocular administration to a patient in need of such treatment of an effective ocular antihypertensive amount of a compound of claim 1.

12. A method of treating ocular hypertension comprising topical ocular administration to a patient in need of such treatment of an effective ocular antihypertensive amount of the compound of claim 6.

13. A method of treating ocular hypertension comprising topical ocular administration to a patient in need of such treatment of an effective ocular antihypertensive amount of the compound of claim 7.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc